fingolimod hydrochloride has been researched along with cytarabine in 1 studies
| Studies (fingolimod hydrochloride) | Trials (fingolimod hydrochloride) | Recent Studies (post-2010) (fingolimod hydrochloride) | Studies (cytarabine) | Trials (cytarabine) | Recent Studies (post-2010) (cytarabine) |
|---|---|---|---|---|---|
| 2,771 | 157 | 2,062 | 15,487 | 2,424 | 3,188 |
| Protein | Taxonomy | fingolimod hydrochloride (IC50) | cytarabine (IC50) |
|---|---|---|---|
| nuclear receptor coactivator 3 isoform a | Homo sapiens (human) | 7.533 | |
| E3 ubiquitin-protein ligase Mdm2 | Homo sapiens (human) | 0.02 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blanco-Prieto, MJ; Castello-Cros, R; Cirauqui, C; Estella-Hermoso de Mendoza, A; Imbuluzqueta, E; Odero, MD; Pippa, R | 1 |
1 other study(ies) available for fingolimod hydrochloride and cytarabine
| Article | Year |
|---|---|
Lipid Nanosystems Enhance the Bioavailability and the Therapeutic Efficacy of FTY720 in Acute Myeloid Leukemia.
Topics: Animals; Antineoplastic Agents; Apoptosis; Caspases; Cell Proliferation; Cytarabine; Drug Delivery Systems; Enzyme Activation; Female; Fingolimod Hydrochloride; HL-60 Cells; Humans; Idarubicin; Leukemia, Myeloid, Acute; Lipids; Mice; Mice, Transgenic; Nanoparticles; Nanotechnology; Propylene Glycols; Sphingosine | 2015 |